Company Encyclopedia
View More
name
Gossamer Bio
GOSS.US
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds.
1.946 T
GOSS.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking216/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE1107.64%A
    • Profit Margin-354.50%E
    • Gross Margin100.00%A
  • Growth ScoreE
    • Revenue YoY-58.17%E
    • Net Profit YoY-117.96%E
    • Total Assets YoY-40.49%E
    • Net Assets YoY-252.09%E
  • Cash ScoreE
    • Cash Flow Margin-28.21%D
    • OCF YoY-58.17%E
  • Operating ScoreD
    • Turnover0.16D
  • Debt ScoreE
    • Gearing Ratio139.43%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Gossamer Bio to Present at Piper Sandler Healthcare Conference

    Gossamer Bio Inc. will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, in New York, NY, and participate in a panel at the Oppenheimer Movers in Rare Disease Summit on December 11, 2025, also in New York, NY. This information is provided by Public Technologies using AI and is not financial advice.

    Reuters·
    US
    GOSS
    -2.92%
    Reuters·
    US
    GOSS
    -2.92%

    Gossamer Bio (NASDAQ:GOSS) Upgraded by Wall Street Zen to "Hold" Rating

    Wall Street Zen upgraded Gossamer Bio (NASDAQ:GOSS) from a "sell" to a "hold" rating. Other analysts have also commented positively, with Wedbush raising the target price from $4.00 to $5.00 and maintaining an "outperform" rating. Gossamer Bio's stock opened at $2.36, with a market cap of $546.25 million. The company reported a revenue of $13.29 million for the last quarter, exceeding estimates. Institutional investors hold 81.23% of the stock. Gossamer Bio focuses on developing treatments for pulmonary arterial hypertension.

    Market Beat·
    US
    GOSS
    -2.92%
    Market Beat·
    US
    GOSS
    -2.92%

    Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

    Gossamer Bio Inc :GOSSAMER BIO ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

    Reuters·
    US
    GOSS
    -2.92%
    Reuters·
    US
    GOSS
    -2.92%

    Gossamer Bio Grants Stock Options to New Employees Under 2023 Inducement Plan

    Gossamer Bio Inc. has granted non-qualified stock options to six non-executive employees, allowing the purchase of 378,996 shares at an exercise price of $2.37 each. The options have a ten-year term and vest over four years, with 25% vesting after one year and the rest in monthly installments. This is part of the company’s 2023 Employment Inducement Incentive Award Plan.

    Reuters·
    US
    GOSS
    -2.92%
    Reuters·
    US
    GOSS
    -2.92%

    Gossamer Bio Inc. to Present at Guggenheim Securities Healthcare Innovation Conference

    Gossamer Bio Inc., a late-stage clinical biopharmaceutical company, will present at the Guggenheim Securities Healthcare Innovation Conference on November 11 in Boston. The focus of the presentation will be on seralutinib, a treatment for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. This announcement is for informational purposes only and should not be considered financial or legal advice.

    Reuters·
    US
    GOSS
    -2.92%
    Reuters·
    US
    GOSS
    -2.92%
    © 2025 Longbridge｜Disclaimer